仿生智能白蛋白纳米递药系统治疗类风湿性关节炎及免疫分子机制研究

批准号:
82003663
项目类别:
青年科学基金项目
资助金额:
24.0 万元
负责人:
胡青
依托单位:
学科分类:
药剂学
结题年份:
2023
批准年份:
2020
项目状态:
已结题
项目参与者:
胡青
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
类风湿性关节炎(RA)是一种最常见的慢性炎症性自身免疫疾病,虽然纳米载体的应用一定程度改善了药物治疗的不足,但其靶向治疗仍面临巨大挑战。本课题旨在构建一种“壳-核”型仿生巨噬细胞膜包被钩吻素子白蛋白自供氧纳米递送系统。该系统首先通过RA炎症病理特征释放的趋化因子与巨噬细胞膜的相互作用,被招募至病灶关节,从而增加药物蓄积。随后白蛋白纳米粒共转运钩吻素子和过氧化氢酶,催化炎症部位的过氧化氢产生氧气,改善RA缺氧微环境的同时,控制药物精准释放,实现药物和供氧的协同高效治疗。在优化构建载体及体内外系统评价的基础上,深入探讨仿生纳米粒免疫调节及其分子作用机制。该递药系统设计简单且高效,具有优良的生物相容性,可作为RA多靶点、多途径治疗的仿生载体,为探索新一代纳米载体治疗RA提供了一个合理且创新的方法。
英文摘要
Rheumatoid arthritis (RA) is one of the most common and severe autoimmune diseases related to joints. Although the application of nanocarriers has improved the deficiencies of drug therapy to a certain extent, its targeted therapy still faces huge challenges. This subject aims to build a macrophage membrane coated koumine-albumin self-oxygenating biomimetic drug delivery system. Through the interaction of chemokines released by the pathological features of RA and macrophage membranes, bionic nanoparticles are recruited to the RA joints, thereby increasing drug accumulation. Subsequent co-loaded catalase catalyzes the production of oxygen by hydrogen peroxide, improves the hypoxia microenvironment of RA, controls drug release, and achieves a synergistic and efficient treatment of drugs and oxygen supply. Based on the optimized construction of the carrier and in vivo and in vitro system evaluation, the immune regulation function of koumine-albumin nanoparticles and its molecular mechanism are discussed in depth. The drug delivery system is simple and efficient in design and has excellent biocompatibility, is an effective bionic carrier for multi-target and multi-channel treatment, and provides a reasonable and innovative method for exploring the new generation of nano-carriers for the treatment of RA.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.1021/acsami.1c21775
发表时间:2022-02-09
期刊:ACS APPLIED MATERIALS & INTERFACES
影响因子:9.5
作者:Hu, Qing;Yao, Jiayi;Yu, Xiangbin
通讯作者:Yu, Xiangbin
DOI:--
发表时间:2021
期刊:Drug Delivery
影响因子:--
作者:Qing Hu;Xiaoling Fu;Yanping Su;Yanfang Wang;Sihuan Gao;Xiaoqin Wang;Ying Xu;Changxi Yu
通讯作者:Changxi Yu
DOI:10.1016/j.ijpharm.2021.120829
发表时间:2021-07-03
期刊:INTERNATIONAL JOURNAL OF PHARMACEUTICS
影响因子:5.8
作者:Hu, Qing;Lin, Han;Yu, Xiangbin
通讯作者:Yu, Xiangbin
DOI:10.2147/ijn.s406641
发表时间:2023
期刊:International journal of nanomedicine
影响因子:8
作者:
通讯作者:
基于红细胞/肿瘤细胞融合膜的仿生无载体纳米药物联合化疗、免疫与化学动力学治疗乳腺癌的研究
- 批准号:2023J01308
- 项目类别:省市级项目
- 资助金额:10.0万元
- 批准年份:2023
- 负责人:胡青
- 依托单位:
国内基金
海外基金
